Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy M Lin

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
BJU International|June 27, 2006
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapyAmy M Lin, Brian I Rini, Vivian Weinberg, et al.
Urologic Oncology|October 2, 2010
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II studyTerence W Friedlander, Vivian K Weinberg, Eric J Small, et al.
Clinical Genitourinary Cancer|July 25, 2007
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancerAmy M Lin, Brian I Rini, Mika K Derynck, et al.
Cancer|March 10, 2011
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinomaAndrea L Harzstark, Eric J Small, Vivian K Weinberg, et al.
Cancer Immunology Research|May 14, 2015
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with IpilimumabSerena S Kwek, Jera Lewis, Li Zhang, et al.
The Oncologist|March 1, 2018
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate CancerXiao X Wei, Adam P Siegel, Rahul Aggarwal, et al.
Cancer Research|January 17, 2009
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSFLawrence Fong, Serena S Kwek, Shaun O'Brien, et al.
Oncology Reports|October 6, 2011
A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancerTerence W Friedlander, Vivian K Weinberg, Yong Huang, et al.
The Journal of Pediatrics|November 17, 2009
Asymptomatic maternal combined homocystinuria and methylmalonic aciduria (cblC) detected through low carnitine levels on newborn screeningHenry J Lin, Julie A Neidich, Denise Salazar, et al.
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
BJU International|June 27, 2006
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapyAmy M Lin, Brian I Rini, Vivian Weinberg, et al.
Urologic Oncology|October 2, 2010
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II studyTerence W Friedlander, Vivian K Weinberg, Eric J Small, et al.
Clinical Genitourinary Cancer|July 25, 2007
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancerAmy M Lin, Brian I Rini, Mika K Derynck, et al.
Cancer|March 10, 2011
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinomaAndrea L Harzstark, Eric J Small, Vivian K Weinberg, et al.
Cancer Immunology Research|May 14, 2015
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with IpilimumabSerena S Kwek, Jera Lewis, Li Zhang, et al.
The Oncologist|March 1, 2018
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate CancerXiao X Wei, Adam P Siegel, Rahul Aggarwal, et al.
Cancer Research|January 17, 2009
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSFLawrence Fong, Serena S Kwek, Shaun O'Brien, et al.
Oncology Reports|October 6, 2011
A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancerTerence W Friedlander, Vivian K Weinberg, Yong Huang, et al.
The Journal of Pediatrics|November 17, 2009
Asymptomatic maternal combined homocystinuria and methylmalonic aciduria (cblC) detected through low carnitine levels on newborn screeningHenry J Lin, Julie A Neidich, Denise Salazar, et al.
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.
Pageof 3